Delivery · Sep 15, 2026
Transdermal Peptide Delivery: What a Patch Can and Cannot Do
Skin is an excellent barrier, and peptides are exactly the kind of molecule it is built to exclude. What patch technology can realistically achieve.
In short
- The stratum corneum excludes large, polar molecules by design.
- The classic rules of thumb favour small lipophilic drugs, not peptides.
- Local delivery and systemic delivery are different claims.
The barrier you are trying to cross
The outermost skin layer, the stratum corneum, is roughly ten to twenty micrometres of flattened dead keratinocytes embedded in a lipid matrix. It exists to stop things getting in and water getting out, and it is very good at it.
The empirical guidance for passive transdermal delivery is unforgiving: molecular weight under about 500 daltons, moderate lipophilicity, and a dose small enough to work at the achievable flux. Successful passive patches — nicotine, fentanyl, scopolamine, hormones — all sit inside that envelope.
Where peptides fall
BPC-157 is a fifteen-residue peptide of roughly 1,419 daltons. It is well above the rule-of-thumb ceiling and it is polar. Passive diffusion across intact stratum corneum is not a plausible primary mechanism at that size.
That does not make every patch worthless. It does mean any credible product has to explain what mechanism it is relying on instead.
The enhancement toolbox
Chemical enhancers — ethanol, terpenes, fatty acids, dimethyl sulfoxide — temporarily disrupt the lipid matrix to raise permeability. They work, and they trade off against skin irritation.
Physical methods go further: microneedles that create transient micron-scale channels through the stratum corneum, iontophoresis using a small current to drive charged molecules, sonophoresis using ultrasound. Microneedle arrays are the most credible route for peptide-sized molecules and are an active area of genuine research.
A dissolving microstructure array is a different product from an adhesive patch with peptide in the glue. Both may be described as a patch.
Local versus systemic
These are separate claims requiring separate evidence. Delivering a peptide into the skin and nearby tissue is a much lower bar than delivering a therapeutic systemic concentration.
A product positioned for local comfort at the application site is making a modest, plausible claim. The same product implying systemic equivalence to an injection is not, and the distinction is frequently blurred.
Questions worth asking
What is the mechanism — passive, enhancer-assisted or microneedle? What is the stated payload per unit, and what fraction is claimed to cross? Is the claim local or systemic? Has permeation been measured, in what model, and is that data available?
A manufacturer that can answer those is doing formulation work. One that answers with adjectives is doing marketing.
Educational content, not medical advice. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Back to research